Mucosal Allergen Immunotherapy Rush Dosing Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current allergen-specific immunotherapy for seasonal allergens requires initiation before the pollen season to avoid adverse events, limiting its effectiveness and accessibility for patients who seek treatment during the pollen season.
Innovation Solution
Administering a seasonal allergen via mucosal routes, either in solid or liquid dosage form, without an up-dosing phase, allowing for initiation of treatment within the allergen season, which is equally well-tolerated and effective as pre-seasonal initiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allergen-specific immunotherapy is initiated before the pollen season to avoid adverse events, then safety is improved, but accessibility and effectiveness for patients seeking treatment during the pollen season deteriorates
Solution Approach 1:
The patent changes the dosing parameters by implementing a rush-up-dosing regimen with gradually increasing doses over 5-7 days when starting therapy during the pollen season, rather than using a fixed low dose. This allows intra-seasonal initiation to be as safe as pre-seasonal initiation while providing accessibility to patients who present during the pollen season
Solution Approach 2:
The patent performs preliminary risk assessment and patient selection before initiating intra-seasonal therapy, identifying patients who are suitable candidates for rush-up-dosing. This preliminary evaluation ensures safety while enabling timely treatment initiation during the pollen season
2Reliability
If conventional dosing regimens with up-dosing phases are used, then safety is improved, but treatment duration and complexity increase
Solution Approach 1:
The patent implements a rush-up-dosing phase that compresses the traditional prolonged up-dosing period into just 5-7 days of gradually increasing doses, followed by immediate maintenance phase. This rushes through the up-dosing process safely while significantly reducing overall treatment duration and getting patients to therapeutic doses faster
Solution Approach 2:
The patent employs dynamic dosing adjustment during the rush-up phase, where doses are increased systematically over 5-7 days based on patient tolerance, then transitions to a stable maintenance phase. This dynamic approach optimizes both safety and time efficiency by adapting the dosing schedule to individual patient responses
3Adaptability or versatility
If treatment is initiated during the pollen season, then accessibility is improved, but the risk of adverse events increases
Solution Approach 1:
The patent changes the dosing parameters by implementing a rush-up-dosing regimen with gradually increasing doses over 5-7 days when starting therapy during the pollen season, rather than using a fixed low dose. This allows intra-seasonal initiation to be as safe as pre-seasonal initiation while providing accessibility to patients who present during the pollen season
Solution Approach 2:
The patent incorporates continuous monitoring and feedback during the rush-up-dosing phase, where patients are closely observed for adverse reactions and dosing is adjusted based on their tolerance. This feedback mechanism enables safe intra-seasonal initiation by detecting and managing potential adverse events in real-time
Data Source
AI summary
The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily. Furthermore, advantageously, the same dose may be used throughout the treatment period since up-dosing is not required.